DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?

Mark Sculpher, PhD

Professor of Health Economics
Centre for Health Economics
University of York, UK

Workshop W6, ISPOR 20th Annual European Congress, Glasgow

A model of HTA emerging internationally?
Cost-effectiveness and price

- Price > P*£60,000
- Price = P* £40,000
- Price < P*£20,000

Measure of opportunity cost £20,000 per QALY


Does this provide an appropriate incentive to manufacturers?

- Is health measured appropriately?
- Are there benefits other than health that should be reflected?
- Should future health gains from major innovation be counted?
- Should each jurisdiction pay a ‘fair share’ to incentivize innovation?
Speakers

Ross Maclean
Senior Vice President, Head of Medical, at Precision Health Economics, USA

Speakers

Karl Claxton
Professor of Economics
University of York, UK
Speakers

**Jens Grueger**  
Head of Global Pricing & Market Access  
Hoffmann-La Roche  
Switzerland